Bristol Myers Squibb Secures FDA Accelerated Approval for CELMoD Therapy ZENBEXUS

Bristol Myers Squibb (NYSE: BMY) won accelerated approval from the U.S. Food and Drug Administration on August 13, 2026, for its novel CELMoD therapy ZENBEXUS in combination with daratumumab, hyaluronidase‑fihj, and dexamethasone (ZDd) for patients with multiple myeloma at first relapse. This marks the company’s first therapy in the CELMoD class to reach commercial stage. According to reports, the accelerated approval designates ZENBEXUS for use as early as the first relapse phase, underlining regulatory confidence in its potential benefit. News of the approval was first reported by Business Wire and Global News Select on August 13, 2026.

The accelerated approval represents a strategic milestone in Bristol Myers Squibb’s oncology portfolio, leveraging its CELMoD platform to address a treatment gap in multiple myeloma. It follows the company’s earlier success with mezigdomide’s New Drug Application acceptance by the FDA in mid‑July, underscoring growing momentum in its pipeline. While the actual FDA decision occurred on August 13, press coverage aligns with that date, not merely the publication dates.

This regulatory gain arrives in the wake of Bristol Myers Squibb’s strong second‑quarter 2026 earnings release on July 30, where the company beat consensus estimates with adjusted EPS of $2.04 and revenue of $12.97 billion. Notably, growth drivers included double‑digit gains across key assets—Eliquis grew 21%, Breyanzi 41%, Camzyos 59%, and Reblozyl 29%. The company raised full‑year guidance following the results.

From a market standpoint, questions arise about how the ZENBEXUS approval might influence investor sentiment and the performance of BMY’s shares. The reported live price as of August 24, 2026, was $67.28, reflecting a decline of 0.19%, but without a disclosed direct market reaction tied explicitly to the approval. No verified source directly links the approval to a stock price move, so any causal statement would be speculative.

Overall, the FDA’s accelerated approval of ZENBEXUS on August 13, 2026, advances Bristol Myers Squibb’s CELMoD ambitions and strengthens its therapeutic offerings in multiple myeloma. Investors should monitor upcoming sales data, commercial rollout timelines, and potential reimbursement developments as key indicators of the therapy’s commercial impact.